Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

INTRODUCTION: Recent years have seen a dramatic escalation of off-label prescribing for gabapentin and pregabalin (gabapentinoids) owing in part to generic versions of each being released over the past two decades, but also in part as a response to increasing calls for multimodal and non-opioid pain...

Descripción completa

Detalles Bibliográficos
Autores principales: McAnally, Heath, Bonnet, Udo, Kaye, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648827/
https://www.ncbi.nlm.nih.gov/pubmed/32737803
http://dx.doi.org/10.1007/s40122-020-00189-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648827/
https://www.ncbi.nlm.nih.gov/pubmed/32737803
http://dx.doi.org/10.1007/s40122-020-00189-x

Ejemplares similares